Overview

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
A dose-escalation study to estimate the maximum tolerated dose(MTD) of CAT-8015 that can be safely administered to a patient.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune LLC
Treatments:
Immunotoxin HA22